It is currently only available within clinical trial settings and is being evaluated for the treatment of obesity and type 2 diabetes
Discontinuation Rates Discontinuation rates due to adverse events in the Phase 2 trial were dose-dependent, ranging from approximately 6% in the 1 mg arm to 16% in the 12 mg arm
In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease
In addition to appetite control, GLP-1 injections can improve insulin sensitivity and help regulate blood sugar levels, which is particularly beneficial for people with obesity or those at risk of developing type 2 diabetes
Larger peptides with post-translational modifications (like the fatty diacid moiety on retatrutide) are more susceptible to degradation than simpler sequences
